Not long ago, the U.S. Department of Justice indicated that it would keep on giving leeway to states that have legalized cannabis, even though marijuana remains illegal at the federal level.
Then yesterday, the DOJ hinted that it would begin cracking down on recreational marijuana – and soon.
“In fact, we’re looking at that very hard right now, we had a meeting yesterday and talked about it at some length,” U.S. Attorney General Jeff Sessions said at a press conference yesterday. “It’s my view that the use of marijuana is detrimental, and we should not give encouragement in any way to it, and it represents a federal violation, which is in the law and is subject to being enforced… We are working our way through to a rational policy, but I don’t want to suggest in any way that this department believes that marijuana is harmless and people should not avoid it.”
Bless his heart.
Now I admire Sessions a lot. I’m with him on big priorities like fighting crime… stopping illegal immigration… and supporting local police departments.
But he has been and continues to be dead wrong on legal recreational marijuana.
Even after stacking up a bunch of double-, triple- and even quadruple-digit gains over the last year and a quarter, many of my Roadmap to Marijuana Millions pot stocks still have plenty of gas left.
In fact, a few of my Canadian legal marijuana plays in particular been on fire for months now – and especially since Nov. 10.
That’s the day Canada’s Department of Finance presented its cannabis tax plan on. The Canadian government plans to add a $1-per-gram excise tax on cannabis products, or 10% of the sale price, whichever is higher. Plus, the tax plan reiterated Canada’s commitment to legalize marijuana by July 2018.
No wonder my readers’ “Fast Fortune” Canadian pot stocks jumped higher.
One of those stocks rose 15% the day that news broke… another soared 10% that day… another jumped 6.8%… and another picked up13%.
But today we’re talking about the one that gained 15% on Nov. 10. We’re focusing on that one because it’s gone on to soar 76% since then thanks to another catalyst entirely. And it’s gained an amazing 766% since I first alerted my readers to it back in September 2016.
Today, I’ll tell you about that stock – and the “second” catalyst that boosted its gains.
Plus, I’ve identified another “trigger” that’s going to boost pot stocks on Jan. 1.
I want you to get in on these stocks before that catalyst hits.
For one, I’m a bit taller than the average guy. My hair went silver earlier than I expected. And I’m fortunate that it’s easier for me to keep trim than a lot of people I know.
On the downside, I’ve got various allergies and genetic maladies that most folks don’t.
My environment isn’t average either. Here in Silicon Valley and the San Francisco Bay Area, I spend my days in some of the most polluted cities in the United States. Of course, in other ways, this region rates much higher than most of America.
Then there are my habits. For example, I eat well, but don’t get to the gym enough.
I bet you’re the same way – but different.
No one is average.
And that’s why it often seems like maintaining a healthy diet, getting plenty of exercise, and regular checkups just aren’t enough to keep us healthy. If it were, no one would gain too much weight, go bald at 30, or get cancer.
By our very nature, each of us is so unique that this one-size-fits-all approach just isn’t enough.
That’s what opened the door for an emerging field known as precision medicine. The idea here is to set up disease prevention and treatment measures for each and every individual, accounting for your genes, environment, and lifestyle… for my genes, environment, and lifestyle.
Think of it as a partnership – a “convergence” – among traditional medicine, molecular biology, data analysis, and cloud computing.
Doctors and other medical diagnosticians collect our info, and then feed it to the cloud. There software and data scientists can crunch through all that data – and then use what they turn up to prescribe precise disease treatments and preventative measures for each individual.
Mordor Intelligence has run the numbers – and says precision medicine will be worth $59.2 billion by 2021
The legal cannabis sector is no longer the “Wild West”-style marketplace it was back in, say, 2013, but there’s still plenty of volatility compared with the placid broader markets.
Then again, that’s why the right pot stocks reward forward-thinking investors with triple- and quadruple-digit gains. In fact, there’s a bevy of micro- and small-cap companies, any one of which could be the next mega-cap blockbuster – the long-sought-after “Starbucks of weed” or “Facebook of pot.”
My Nova-X Report’s Roadmap to Marijuana Millions model portfolio is chock-full of that kind of stocks. Right now my paid-up members are sitting on gains of 915%… 520.6%… 442.7%… and five more triple-digit winners. If you’d like to find out how to take advantage of this green revolution and get in on gains like those, click here.
But I don’t want to leave anyone with the impression that the only way to make a killing on pot stocks is to buy small, volatile companies. The gains from my Scotts Miracle-Gro Co. (NYSE: SMG) and GW Pharmaceuticals PLC (Nasdaq: GWPH) recommendations prove that just isn’t the case.
Then there’s the company I want to tell you about today.
It isn’t likely to quadruple your money quickly, but you’ll likely smash the market with double- and even triple-digit gains, and it pays a dividend that puts you way out ahead of inflation and low interest rates, too.
As the hardware chief at Facebook Inc. (Nasdaq: FB), Frankovsky’s team invented a way to use Blu-ray discs to save the oodles of photos that we all upload on that site every day. While Facebook still keeps its frequently accessed data on hard or flash drives, its deeper archives now reside on thousands of Blu-rays.
Frankovsky’s system – which involves robotic arms, thousands of discs, and hundreds of racks – turned out to be tremendously successful for the social-media giant. Facebook says the system cut costs by 50% and energy use by 80% compared to the hard disk drive system it was using.
So it’s no surprise that Frankovsky broke off from his “corporate overlords” back in 2014, opened up his own shop – Optical Archive Inc. – and started selling his system to other companies with Big Data storage needs.
If you’ve never heard of Frankovsky, that’s okay.
His beard may be a bit flamboyant – but he and Optical Archive operated in what I like to call “stealth mode”… quiet and under the radar.
But one once-struggling tech giant saw what was going on – and bought Frankovsky’s company in 2015.
That company was also operating in stealth mode at the time. After years of decline, it needed to stay quiet in order to rebuild.
In fact, around that time, it made three big stealth moves that have now put it back on the map.
It’s no longer in stealth mode… it’s absolutely crushing the market… and it’s just getting restarted.
Today I’ll tell you about the three big moves it made.
And I’ll show you how you can join in – and ride along as reclaims its place as one of the world’s preeminent technology companies.
Tension in the Middle East and the South China Sea… a political mess at home… sky-high stock prices.
And here’s something else to worry about…
On Nov. 1, a Wall Street Journal headline warned about the “Consumer Confidence Conundrum.”
Here’s the worry: According to WSJ writer Chris Dieterich and the folks he talked, because consumer confidence is at its highest level since December 2000, it’s time to “add this to the list of reasons investors ought to be getting nervous.”
The reason: It may signal the bull market is coming to an end.
Thanks to legal recreational use of marijuana about to launch in California and nationwide up in Canada, sometimes it’s easy to forget where we got started here.
Legal marijuana first came to my attention because of the “War on Pain.”
Let me explain…
In a study a year or so ago, the National Institutes of Health (NIH) found that about 11% of Americans suffered from debilitating pain. Other sources say the number of this country’s pain sufferers may run as high as 50 million.
But I don’t need statistics to know that millions of Americans suffer from serious pain problems.
I do so myself – and so do many of my friends and family members.
And that has turned the market for pain medication into a huge business. According to market researcher VisionGain, the worldwide business for pain drugs is worth about $68 billion right now.
Other studies say it’s even bigger.
Equally huge is the nation’s opioid crisis.
President Donald Trump has declared the opioid crisis a “public health emergency,” and a White House commission has released its final report on the epidemic, calling for more drug courts, greater training for doctors, and penalties for insurers who do not cover addiction treatment.
The number of opioid-related deaths rose 75%, from roughly 20,000 in 2010 to 35,000 in 2015. In other words, opioid-based drugs kill more than 100 Americans every day.
This surge in the number of pain sufferers – coupled with the snapback against the prescription of opioid drugs – has opened the door to a wholly new approach to pain treatment.
I’m talking about medical marijuana and all its derivatives.